Clinical Trials Logo

Clinical Trial Summary

This is a Phase 1, randomized, double-blind, placebo-controlled single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VK2735 in healthy adults and otherwise healthy adults who have an increased body mass index (BMI).


Clinical Trial Description

This study comprises 2 parts: Part A (Single Ascending Dose [SAD]) will be conducted to assess the safety, tolerability, and PK profile in healthy participants following 1 single SC injection of VK2735 or VK2735 matching placebo (SAD Cohort 1 through SAD Cohort 6). Part B (Multiple Ascending Dose [MAD]) will be conducted to assess the safety, tolerability, PK and PD profile in otherwise healthy participants who have an increased BMI following single SC injections of VK2735 or matched placebo administered once weekly for 4 consecutive weeks (MAD Cohort 1 through MAD Cohort 5). Safety Review Committee (SRC) meetings will be held prior to dose escalation for both the Part A (SAD) and Part B (MAD) cohorts in the study. The decisions on dose escalation will be based on safety and laboratory data from each cohort. ;


Study Design


Related Conditions & MeSH terms

  • Fatty Liver
  • NASH - Nonalcoholic Steatohepatitis
  • Non-alcoholic Fatty Liver Disease

NCT number NCT05203237
Study type Interventional
Source Viking Therapeutics, Inc.
Contact Marianne Mancini
Phone 858-704-4674
Email [email protected]
Status Recruiting
Phase Phase 1
Start date December 14, 2021
Completion date December 2022

See also
  Status Clinical Trial Phase
Completed NCT03289897 - Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan N/A
Recruiting NCT04976283 - Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver Phase 4
Completed NCT02784444 - A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH Phase 2
Active, not recruiting NCT04321343 - Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH) Phase 2
Recruiting NCT04371042 - PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
Not yet recruiting NCT03648554 - Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST) Phase 4
Recruiting NCT04972396 - ALT-801 DDI Study in Healthy Volunteers Phase 1
Completed NCT03748628 - Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects Phase 1
Recruiting NCT04643795 - Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects Phase 1
Not yet recruiting NCT04781933 - Interest in "Combo" (a Combination of Dietary Supplements Including Probiotics) in NASH Improvement N/A
Active, not recruiting NCT04066400 - Role of a Wheat Containing Diet on Non-alcoholic Steatohepatitis N/A
Completed NCT03536650 - Effect of DMR in the Treatment of NASH N/A
Completed NCT03783897 - A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects Phase 1
Recruiting NCT04618744 - A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH) Phase 2
Recruiting NCT05338034 - Phase 2a Study of HPG1860 in Subjects With NASH Phase 2
Active, not recruiting NCT04653103 - NASH in Subjects With Different Classes of Obesity
Recruiting NCT04173065 - A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH Phase 2
Active, not recruiting NCT04685993 - A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial Phase 2
Completed NCT04561245 - ALT-801 in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability Phase 1
Enrolling by invitation NCT04841057 - Biometabolic Outcomes After Weight Loss Surgery: An Individualized Approach N/A